Patents Assigned to Bristol-Myers Company
  • Patent number: 4912133
    Abstract: A new antitumor antibiotic designated herein as BU-3862T is produced by fermentation of Streptomyces hygroscopicus ATCC 53709. BU-3862T and its diacetyl and dihydro derivatives inhibit the growth of tumors in experimental animals.
    Type: Grant
    Filed: March 7, 1988
    Date of Patent: March 27, 1990
    Assignee: Bristol-Myers Company
    Inventors: Koko Sugawara, Masami Hatori, Hideo Kamei, Masataka Konishi, Toshikazu Oki, Koji Tomita
  • Patent number: 4910301
    Abstract: Crystalline sulfuric, di-nitric, mono-hydrochloric, di-hydrochloric, and di- and sesqui-orthosphosphoric acid addition salts of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(Z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinio)methyl]-3-cephem-4-carboxylate are stable even at elevated temperatures. The crystalline sulfuric acid addition salt is made by forming an admixture of (a) at least one molar equivalent of sulfuric acid with (b) zwitterion in an amount so as to be present in the admixture at a concentration of greater than 25 milligrams/ml, causing crystallization, separating the crystals, washing and drying. The crystalline monohydrochloride, dihydrochloride, and orthophosphate salts are prepared by dissolving the zwitterion in the appropriate amount of acid, causing crystallization by adding acetone and isolating the crystals. Physical admixtures of the salts with certain bases in proportions to give a pH ranging from about 3.
    Type: Grant
    Filed: January 19, 1988
    Date of Patent: March 20, 1990
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Thomas W. Hudyma, Robert A. Lipper, Kun M. Shih, Susan D. Boettger
  • Patent number: 4908440
    Abstract: There are disclosed novel 2',3'-dideoxy-2'-fluoronucleosides and 2'-3'-dideoxy-2',3'-didehydro-2'-fluoronucleosides and processes for their preparation. The compounds so produced exhibit therapeutically useful antiviral and, more particularly, anti-HIV effects.
    Type: Grant
    Filed: November 12, 1987
    Date of Patent: March 13, 1990
    Assignee: Bristol Myers Company
    Inventors: Roman Z. Sterzycki, Muzammil M. Mansuri, John C. Martin
  • Patent number: 4904768
    Abstract: Phosphate derivatives of 4'-demethylepipodophyllotoxin glucosides are novel antitumor agents and the salts thereof offer the pharmaceutical advantage of high water solubility.
    Type: Grant
    Filed: May 27, 1988
    Date of Patent: February 27, 1990
    Assignee: Bristol-Myers Company
    Inventors: Mark G. Saulnier, Peter D. Senter, John F. Kadow
  • Patent number: 4904770
    Abstract: There are disclosed novel processes for producing 2',3'-dideoxy-2'3'-didehydronucleosides, for example, 2',3'-dideoxy-2',3'-didehydrothymidine in high yields and on a large scale. The compounds so-produced are useful as antiviral agents, especially as agents effective against the human immunodeficiency viruses (HIV).
    Type: Grant
    Filed: March 24, 1988
    Date of Patent: February 27, 1990
    Assignee: Bristol-Myers Company
    Inventors: John E. Starrett, Jr., Muzammil M. Mansuri, John C. Martin, Carl E. Fuller, Henry G. Howell
  • Patent number: 4898950
    Abstract: This invention provides novel intermediates of the formula ##STR1## in substantially the cis or cis-(4R,6S) form wherein R.sup.9 and R.sup.10 each are C.sub.1-4 alkyl or R.sup.9 and R.sup.10, taken together with the carbon atom to which they are attached, is cyclopentyl, cyclohexyl or cycloheptyl; andR.sup.12 is hydrogen, C.sub.1-4 alkyl or a metal cationand processes thereof which are useful for the preparation of antihypercholesterolemic agents.
    Type: Grant
    Filed: February 6, 1989
    Date of Patent: February 6, 1990
    Assignee: Bristol-Myers Company
    Inventors: William T. Han, John J. Wright
  • Patent number: 4898940
    Abstract: Novel peptides of the formula ##STR1## wherein R is CH.sub.3 --(CH.sub.2).sub.6, CH.sub.3 --(CH.sub.2).sub.4 --CH.dbd.CH--(CH.sub.2).sub.2 and CH.sub.3 (CH.sub.2).sub.8 having antibiotic and antitumor activity are prepared by cultivation of the novel microorganism Polyangium brachysporum. Enzymatic hydrolysis of those peptides gives other peptides usfeul as intermediates in the preparation of peptides having activity as antibiotics and/or antitumor agents.
    Type: Grant
    Filed: February 13, 1989
    Date of Patent: February 6, 1990
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Koji Tomita, Masahisa Oka, Ken-ichi Numata
  • Patent number: 4898949
    Abstract: This invention provides novel tetrazole intermediates of the formula ##STR1## wherein R.sup.1 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or trifluoromethyl;R.sup.2,R.sup.3,R.sup.5 and R.sup.6 each are independently hydrogen, halogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy;B is hydrogen, C.sub.1-4 alkoxycarbonyl, CH.sub.2 Y or CH.sub.2 Z;Y is hydrogen, hydroxyl or X;Z is ##STR2## X is bromo, chloro or iodo; R.sup.10 is C.sub.1-4 alkyl; andR.sup.11 is phenyl which is unsubstituted or substituted by one or two C.sub.1-4 alkyl or chloro substituents.and processes thereof which are useful for the preparation of antihypercholesterolemic agents.
    Type: Grant
    Filed: February 18, 1988
    Date of Patent: February 6, 1990
    Assignee: Bristol-Myers Company
    Inventors: John J. Wright, Sing-Yuen Sit, Neelakantan Balasubramanian, Peter J. Brown
  • Patent number: 4897259
    Abstract: High oil phase pharmaceutical vehicles in the form of an emulsion system having an oil phase content of from about 35% to about 65%, wherein the emulsion system comprises from about 1% to about 13% of an alkylated PVP copolymer, from about 1% to about 7% of an emulsifier, and a solvent system. The solvent system comprises from about 4% to about 18% of a C.sub.4 -C.sub.22 fatty acid, alcohol or ester thereof, from about 2% to about 25% of a glycol ester or diester, and from 0% to about 13% of a branched chain ester of a C.sub.4 -C.sub.22 carboxylic acid. The pharmaceutical vehicles are useful in sunscreen formulations, and especially those containing higher concentrations of benzophenone-3. When such higher concentrations are used, it is advantageous to add up to about 10% of a branched chain ester of a C.sub.4 -C.sub.22 carboxylic acid.
    Type: Grant
    Filed: November 7, 1988
    Date of Patent: January 30, 1990
    Assignee: Bristol-Myers Company
    Inventors: Terrence J. Murray, Bhiku G. Patel, Richard O. Muhlhauser
  • Patent number: 4895939
    Abstract: Disclosed herein is a novel high .beta.-yield producing novel intermediates of the formula ##STR1## where R.sup.4 is ##STR2## useful in the synthesis of 1-.beta.-alkyl carbapenems.
    Type: Grant
    Filed: June 14, 1988
    Date of Patent: January 23, 1990
    Assignee: Bristol-Myers Company
    Inventors: Alain Martel, Jean-Paul Daris, Jacques Corbeil
  • Patent number: 4895846
    Abstract: A series of 1,4-dihydropyridin-3,5-yl dicarboxylic acid amides and esters incorporating an arylpiperazinylalkyl moiety have been prepared possessing the general formula ##STR1## wherein R.sup.4 is cycloalkyl, aryl or hetaryl, generally with electron-withdrawing substituents; R.sup.2 and R.sup.6 are lower alkyl, alkanol, alkoxyalkyl, or alkylaminoalkyl; R.sup.5 is R.sup.2 or arylpiperazinylalkyl; X is O or NH; Y is lower alkylene, alkoxyalkylene, alkylaminoalkylene; and Z is phenyl, substituted pheny, pyridinyl, substituted pyridinyl, or pyrimidinyl. Compounds of this series demonstrate activity as calcium and alpha-adrenergic blockers in in vitro testing and antihypertensive, anti-ischemic, and platelet function inhibiting actions in in vivo screens.
    Type: Grant
    Filed: December 18, 1987
    Date of Patent: January 23, 1990
    Assignee: Bristol-Myers Company
    Inventors: Graham S. Poindexter, Davis L. Temple, Jr.
  • Patent number: 4890944
    Abstract: A container and delivery system for storing and delivering material (preferably in stick form) to a surface which comprises a product holding portion and a product advancing portion, the producing holding portion being formed into a cap forming section and a product section, the cap forming section being adapted to be separated from the product section and inverted to serve as a cap for the system.
    Type: Grant
    Filed: December 27, 1983
    Date of Patent: January 2, 1990
    Assignee: Bristol-Myers Company
    Inventors: Michael A. Cousins, June Lee
  • Patent number: 4888419
    Abstract: This invention relates to novel 3'-demethoxy epipodophyllotoxin glucosides, their use as anti-tumor agents, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: August 31, 1987
    Date of Patent: December 19, 1989
    Assignee: Bristol-Myers Company
    Inventors: Mark G. Saulnier, Dolatrai M. Vyas
  • Patent number: 4888357
    Abstract: Disclosed herein are novel .beta.-cycloalkyl-.beta.-oxopropionitriles which exhibit anti-inflammatory/antiarthritic activities.
    Type: Grant
    Filed: January 26, 1988
    Date of Patent: December 19, 1989
    Assignee: Bristol-Myers Company
    Inventor: William T. Han
  • Patent number: 4888343
    Abstract: A pharmaceutical composition for relieving symptoms of dysmenorrhea and/or premenstrual syndrome comprising a combination of aspirin or ibuprofen and a diuretic from the group pamabrom and hydrochlorothiazide; optionally it may also contain an antihistamine.
    Type: Grant
    Filed: September 15, 1986
    Date of Patent: December 19, 1989
    Assignee: Bristol-Myers Company
    Inventors: Howard Jones, Alison B. Lukacsko, Thomas M. Tencza, Beth A. Sarsfield, Mahesh K. Patel
  • Patent number: 4883758
    Abstract: The compound 3,7-dihydroxytropolone having the formula ##STR1## is produced by fermentation of Streptomyces tropolofaciens and is found to inhibit the growth of mammalian tumors.
    Type: Grant
    Filed: January 6, 1989
    Date of Patent: November 28, 1989
    Assignee: Bristol-Myers Company
    Inventors: Hideo Kamei, Masaru Ohbayashi, Koji Tomita, Koko Sugawara, Masataka Konishi
  • Patent number: 4882472
    Abstract: A fluoride supplement calculator utilizes two concentrically positioned relatively rotatable disks. A front disk has a plurality of fluoride level apertures which overlie groups of fluoride dosage amounts carried on the second disk. An age scale is also placed on the obverse surface of the second disk. The second disk has a single aperture which is used in conjunction with the reverse surface of the first disk to depict fluoride uptake and enamel formation in teeth of patients of various ages.
    Type: Grant
    Filed: January 5, 1989
    Date of Patent: November 21, 1989
    Assignee: Bristol-Myers Company
    Inventors: Susan J. Sigman, Paula A. Meade
  • Patent number: 4880922
    Abstract: A novel series of carbapenem derivatives characterized by a 2-substituent of the formula ##STR1## in which n has a value of 1, 2 or 3; R.sup.5 represents an optionally substituted aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroaraliphatic, heterocyclyl or heterocyclylaliphatic radical; and ##STR2## represents a quaternized nitrogen-containing aromatic heterocycle bonded to the group --S--(CH.sub.2)n--S-- via a ring carbon atom.
    Type: Grant
    Filed: November 22, 1985
    Date of Patent: November 14, 1989
    Assignee: Bristol-Myers Company
    Inventor: Pierre Dextraze
  • Patent number: 4879377
    Abstract: Process for producing 1-halo-2-deoxy-2-fluoroarabinofuranoside derivatives bearing protective ester groups from 1,3,5-tri-O-acylribofuranose; the 1-halo compounds are intermediates in the synthesis of therapeutically active nucleosidic compounds.
    Type: Grant
    Filed: July 28, 1988
    Date of Patent: November 7, 1989
    Assignee: Bristol-Myers Company
    Inventors: Steven P. Brundidge, Henry G. Howell, Chester Sapino, Jr., Chou Hong-Tann
  • Patent number: 4874779
    Abstract: Disclosed herein are N.sup.7 -alkylphosphate derivatives of mitomycin C and porfiromycin showing antitumor activity against transplanted human tumor and reduced toxicity relative to the parent N.sup.7 -alkanol mitomycin compounds.
    Type: Grant
    Filed: June 29, 1988
    Date of Patent: October 17, 1989
    Assignee: Bristol-Myers Company
    Inventor: Peter D. Senter